Related Experiment Video
Updated: Jul 14, 2026
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
Long-term outcome for lymph node-positive prostate cancer.
G P Swanson1, M W Riggs, M Herman
1The Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA. gswanson@ctrc.net
Prostate Cancer and Prostatic Diseases
|May 24, 2007
Summary
Long-term follow-up of men with lymph node-positive prostate cancer shows 10-year survival is 56%. Adding androgen ablation improves tumor control duration, but optimal timing requires further study.
Area of Science:
- Oncology
- Urology
Background:
- Lymph node-positive prostate cancer, while declining, still presents a significant treatment challenge.
- Long-term outcomes are crucial for evaluating prostate cancer treatment efficacy.
Purpose of the Study:
- To evaluate the long-term outcomes of treating men with lymph node-positive prostate cancer.
- To assess the impact of treatment strategies on survival and tumor control.
Main Methods:
- Retrospective analysis of patients with lymph node-positive prostate cancer.
- Median follow-up duration of 10.2 years.
- Survival rates and tumor control duration were analyzed.
Main Results:
- Overall 5-year survival rate was 78%.
- Overall 10-year survival rate was 56%.
- Androgen ablation significantly improved the duration of tumor control.
Conclusions:
- Long-term survival for lymph node-positive prostate cancer remains a challenge.
- Androgen ablation is a key treatment modality for improving tumor control, though its optimal timing needs further investigation.